Sage Therapeutics scraps plans for Parkinson’s drug after mid-stage failure
Sage Therapeutics said it will stop development of its experimental drug to treat Parkinson’s disease after the treatment failed a mid-stage study, sending the company’s shares tumbling 36% before the bell.